Review



human t lymphoblast cell line  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    ATCC human t lymphoblast cell line
    Human T Lymphoblast Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 93 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human t lymphoblast cell line/product/ATCC
    Average 94 stars, based on 93 article reviews
    human t lymphoblast cell line - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    human t lymphoblast cell line  (ATCC)
    94
    ATCC human t lymphoblast cell line
    Human T Lymphoblast Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human t lymphoblast cell line/product/ATCC
    Average 94 stars, based on 1 article reviews
    human t lymphoblast cell line - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    t cell lymphoblastic human leukemia cell line molt 4  (ATCC)
    99
    ATCC t cell lymphoblastic human leukemia cell line molt 4
    T Cell Lymphoblastic Human Leukemia Cell Line Molt 4, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/t cell lymphoblastic human leukemia cell line molt 4/product/ATCC
    Average 99 stars, based on 1 article reviews
    t cell lymphoblastic human leukemia cell line molt 4 - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    human t lymphoblast cell line jurkat  (ATCC)
    99
    ATCC human t lymphoblast cell line jurkat
    Efferocytosis of apoptotic <t>Jurkat</t> cells labeled with CellTrace™ Violet by CD66b-positive granulocytes stained with CellTrace™ Far Red was examined under various conditions. (A) PMNs were exposed to varying concentrations of β2m or dK58β2m in the presence of apoptotic Jurkat cells. (B) PMNs were treated with apoptotic cells alone or in combination with 50 µg/ml β2m, 50 µg/ml dK58β2m, 100 ng/ml GM-CSF, or combinations thereof. (C-D) PMNs were treated with apoptotic Jurkat cells with 50 µg/ml β2m (C) or dK58β2m (D) combined with 10 or 25% human AB serum. In all experiments, a 4:1 apoptotic cell-to-PMN ratio was used. Treatment with 100 ng/ml GM-CSF served as a positive control, and pre-incubation with 10 µg/ml cytochalasin D (cyto D) served as a negative control. Results are shown as mean ± SD of double-positive PMNs. Sample sizes were n=6 or n=4 (A), n=10 (B), and n=8 or 3 donors (C and D). Group comparisons were analyzed using mixed-effects analysis and Tukey’s multiple comparisons test (A, C, and D) or repeated-measures ANOVA and Tukey’s multiplecomparisons test(B). Statistical significance is indicated by *P < 0.05 and **P < 0.01, ***P < 0.001, ****P < 0.0001.
    Human T Lymphoblast Cell Line Jurkat, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human t lymphoblast cell line jurkat/product/ATCC
    Average 99 stars, based on 1 article reviews
    human t lymphoblast cell line jurkat - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    human tap deficient t2 lymphoblast cell line  (ATCC)
    97
    ATCC human tap deficient t2 lymphoblast cell line
    Efferocytosis of apoptotic <t>Jurkat</t> cells labeled with CellTrace™ Violet by CD66b-positive granulocytes stained with CellTrace™ Far Red was examined under various conditions. (A) PMNs were exposed to varying concentrations of β2m or dK58β2m in the presence of apoptotic Jurkat cells. (B) PMNs were treated with apoptotic cells alone or in combination with 50 µg/ml β2m, 50 µg/ml dK58β2m, 100 ng/ml GM-CSF, or combinations thereof. (C-D) PMNs were treated with apoptotic Jurkat cells with 50 µg/ml β2m (C) or dK58β2m (D) combined with 10 or 25% human AB serum. In all experiments, a 4:1 apoptotic cell-to-PMN ratio was used. Treatment with 100 ng/ml GM-CSF served as a positive control, and pre-incubation with 10 µg/ml cytochalasin D (cyto D) served as a negative control. Results are shown as mean ± SD of double-positive PMNs. Sample sizes were n=6 or n=4 (A), n=10 (B), and n=8 or 3 donors (C and D). Group comparisons were analyzed using mixed-effects analysis and Tukey’s multiple comparisons test (A, C, and D) or repeated-measures ANOVA and Tukey’s multiplecomparisons test(B). Statistical significance is indicated by *P < 0.05 and **P < 0.01, ***P < 0.001, ****P < 0.0001.
    Human Tap Deficient T2 Lymphoblast Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human tap deficient t2 lymphoblast cell line/product/ATCC
    Average 97 stars, based on 1 article reviews
    human tap deficient t2 lymphoblast cell line - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    human lymphoblast cell line  (ATCC)
    97
    ATCC human lymphoblast cell line
    Efferocytosis of apoptotic <t>Jurkat</t> cells labeled with CellTrace™ Violet by CD66b-positive granulocytes stained with CellTrace™ Far Red was examined under various conditions. (A) PMNs were exposed to varying concentrations of β2m or dK58β2m in the presence of apoptotic Jurkat cells. (B) PMNs were treated with apoptotic cells alone or in combination with 50 µg/ml β2m, 50 µg/ml dK58β2m, 100 ng/ml GM-CSF, or combinations thereof. (C-D) PMNs were treated with apoptotic Jurkat cells with 50 µg/ml β2m (C) or dK58β2m (D) combined with 10 or 25% human AB serum. In all experiments, a 4:1 apoptotic cell-to-PMN ratio was used. Treatment with 100 ng/ml GM-CSF served as a positive control, and pre-incubation with 10 µg/ml cytochalasin D (cyto D) served as a negative control. Results are shown as mean ± SD of double-positive PMNs. Sample sizes were n=6 or n=4 (A), n=10 (B), and n=8 or 3 donors (C and D). Group comparisons were analyzed using mixed-effects analysis and Tukey’s multiple comparisons test (A, C, and D) or repeated-measures ANOVA and Tukey’s multiplecomparisons test(B). Statistical significance is indicated by *P < 0.05 and **P < 0.01, ***P < 0.001, ****P < 0.0001.
    Human Lymphoblast Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human lymphoblast cell line/product/ATCC
    Average 97 stars, based on 1 article reviews
    human lymphoblast cell line - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    human t lymphoblast cell lines jurkat  (Korean Cell Line Bank)
    90
    Korean Cell Line Bank human t lymphoblast cell lines jurkat
    Efferocytosis of apoptotic <t>Jurkat</t> cells labeled with CellTrace™ Violet by CD66b-positive granulocytes stained with CellTrace™ Far Red was examined under various conditions. (A) PMNs were exposed to varying concentrations of β2m or dK58β2m in the presence of apoptotic Jurkat cells. (B) PMNs were treated with apoptotic cells alone or in combination with 50 µg/ml β2m, 50 µg/ml dK58β2m, 100 ng/ml GM-CSF, or combinations thereof. (C-D) PMNs were treated with apoptotic Jurkat cells with 50 µg/ml β2m (C) or dK58β2m (D) combined with 10 or 25% human AB serum. In all experiments, a 4:1 apoptotic cell-to-PMN ratio was used. Treatment with 100 ng/ml GM-CSF served as a positive control, and pre-incubation with 10 µg/ml cytochalasin D (cyto D) served as a negative control. Results are shown as mean ± SD of double-positive PMNs. Sample sizes were n=6 or n=4 (A), n=10 (B), and n=8 or 3 donors (C and D). Group comparisons were analyzed using mixed-effects analysis and Tukey’s multiple comparisons test (A, C, and D) or repeated-measures ANOVA and Tukey’s multiplecomparisons test(B). Statistical significance is indicated by *P < 0.05 and **P < 0.01, ***P < 0.001, ****P < 0.0001.
    Human T Lymphoblast Cell Lines Jurkat, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human t lymphoblast cell lines jurkat/product/Korean Cell Line Bank
    Average 90 stars, based on 1 article reviews
    human t lymphoblast cell lines jurkat - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human acute lymphoblastic leukemia cell line molt-4  (National Centre for Cell Science)
    90
    National Centre for Cell Science human acute lymphoblastic leukemia cell line molt-4
    Efferocytosis of apoptotic <t>Jurkat</t> cells labeled with CellTrace™ Violet by CD66b-positive granulocytes stained with CellTrace™ Far Red was examined under various conditions. (A) PMNs were exposed to varying concentrations of β2m or dK58β2m in the presence of apoptotic Jurkat cells. (B) PMNs were treated with apoptotic cells alone or in combination with 50 µg/ml β2m, 50 µg/ml dK58β2m, 100 ng/ml GM-CSF, or combinations thereof. (C-D) PMNs were treated with apoptotic Jurkat cells with 50 µg/ml β2m (C) or dK58β2m (D) combined with 10 or 25% human AB serum. In all experiments, a 4:1 apoptotic cell-to-PMN ratio was used. Treatment with 100 ng/ml GM-CSF served as a positive control, and pre-incubation with 10 µg/ml cytochalasin D (cyto D) served as a negative control. Results are shown as mean ± SD of double-positive PMNs. Sample sizes were n=6 or n=4 (A), n=10 (B), and n=8 or 3 donors (C and D). Group comparisons were analyzed using mixed-effects analysis and Tukey’s multiple comparisons test (A, C, and D) or repeated-measures ANOVA and Tukey’s multiplecomparisons test(B). Statistical significance is indicated by *P < 0.05 and **P < 0.01, ***P < 0.001, ****P < 0.0001.
    Human Acute Lymphoblastic Leukemia Cell Line Molt 4, supplied by National Centre for Cell Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human acute lymphoblastic leukemia cell line molt-4/product/National Centre for Cell Science
    Average 90 stars, based on 1 article reviews
    human acute lymphoblastic leukemia cell line molt-4 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    u937 human lymphoblast monocytes cell line  (ATCC)
    99
    ATCC u937 human lymphoblast monocytes cell line
    Efferocytosis of apoptotic <t>Jurkat</t> cells labeled with CellTrace™ Violet by CD66b-positive granulocytes stained with CellTrace™ Far Red was examined under various conditions. (A) PMNs were exposed to varying concentrations of β2m or dK58β2m in the presence of apoptotic Jurkat cells. (B) PMNs were treated with apoptotic cells alone or in combination with 50 µg/ml β2m, 50 µg/ml dK58β2m, 100 ng/ml GM-CSF, or combinations thereof. (C-D) PMNs were treated with apoptotic Jurkat cells with 50 µg/ml β2m (C) or dK58β2m (D) combined with 10 or 25% human AB serum. In all experiments, a 4:1 apoptotic cell-to-PMN ratio was used. Treatment with 100 ng/ml GM-CSF served as a positive control, and pre-incubation with 10 µg/ml cytochalasin D (cyto D) served as a negative control. Results are shown as mean ± SD of double-positive PMNs. Sample sizes were n=6 or n=4 (A), n=10 (B), and n=8 or 3 donors (C and D). Group comparisons were analyzed using mixed-effects analysis and Tukey’s multiple comparisons test (A, C, and D) or repeated-measures ANOVA and Tukey’s multiplecomparisons test(B). Statistical significance is indicated by *P < 0.05 and **P < 0.01, ***P < 0.001, ****P < 0.0001.
    U937 Human Lymphoblast Monocytes Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/u937 human lymphoblast monocytes cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    u937 human lymphoblast monocytes cell line - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Efferocytosis of apoptotic Jurkat cells labeled with CellTrace™ Violet by CD66b-positive granulocytes stained with CellTrace™ Far Red was examined under various conditions. (A) PMNs were exposed to varying concentrations of β2m or dK58β2m in the presence of apoptotic Jurkat cells. (B) PMNs were treated with apoptotic cells alone or in combination with 50 µg/ml β2m, 50 µg/ml dK58β2m, 100 ng/ml GM-CSF, or combinations thereof. (C-D) PMNs were treated with apoptotic Jurkat cells with 50 µg/ml β2m (C) or dK58β2m (D) combined with 10 or 25% human AB serum. In all experiments, a 4:1 apoptotic cell-to-PMN ratio was used. Treatment with 100 ng/ml GM-CSF served as a positive control, and pre-incubation with 10 µg/ml cytochalasin D (cyto D) served as a negative control. Results are shown as mean ± SD of double-positive PMNs. Sample sizes were n=6 or n=4 (A), n=10 (B), and n=8 or 3 donors (C and D). Group comparisons were analyzed using mixed-effects analysis and Tukey’s multiple comparisons test (A, C, and D) or repeated-measures ANOVA and Tukey’s multiplecomparisons test(B). Statistical significance is indicated by *P < 0.05 and **P < 0.01, ***P < 0.001, ****P < 0.0001.

    Journal: bioRxiv

    Article Title: Beta-2-microglobulin stimulates neutrophil phagocytosis of bacteria and apoptotic cells

    doi: 10.1101/2025.10.30.685267

    Figure Lengend Snippet: Efferocytosis of apoptotic Jurkat cells labeled with CellTrace™ Violet by CD66b-positive granulocytes stained with CellTrace™ Far Red was examined under various conditions. (A) PMNs were exposed to varying concentrations of β2m or dK58β2m in the presence of apoptotic Jurkat cells. (B) PMNs were treated with apoptotic cells alone or in combination with 50 µg/ml β2m, 50 µg/ml dK58β2m, 100 ng/ml GM-CSF, or combinations thereof. (C-D) PMNs were treated with apoptotic Jurkat cells with 50 µg/ml β2m (C) or dK58β2m (D) combined with 10 or 25% human AB serum. In all experiments, a 4:1 apoptotic cell-to-PMN ratio was used. Treatment with 100 ng/ml GM-CSF served as a positive control, and pre-incubation with 10 µg/ml cytochalasin D (cyto D) served as a negative control. Results are shown as mean ± SD of double-positive PMNs. Sample sizes were n=6 or n=4 (A), n=10 (B), and n=8 or 3 donors (C and D). Group comparisons were analyzed using mixed-effects analysis and Tukey’s multiple comparisons test (A, C, and D) or repeated-measures ANOVA and Tukey’s multiplecomparisons test(B). Statistical significance is indicated by *P < 0.05 and **P < 0.01, ***P < 0.001, ****P < 0.0001.

    Article Snippet: The human T lymphoblast cell line Jurkat (TIB-152TM, ATCC®) was cultured in RPMI 1640 medium supplemented with 1% L-glutamine, 1% penicillin and streptomycin, and 10% fetal bovine serum (FBS; Corning, #35–079-CV) at 37°C with 5% CO 2 .

    Techniques: Labeling, Staining, Positive Control, Incubation, Negative Control